Alcobra Pharma, an emerging company focused on the development of new medications to help patients with cognitive disorders, has announced financial results for the fourth quarter and fiscal year ended December 31, 2014, and provided a business update.
The company reported ($0.50) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.57) by $0.07. They set a 'buy' rating and a $10.00 price target on the stock. Analysts at Zacks downgraded shares of Alcobra from an 'outperform' rating to a 'neutral' rating and set a $3.90 price target on the stock in a research note on Wednesday, November 26th.
AdvertisementFinally, analysts at Aegis downgraded shares of Alcobra from a 'buy' rating to a "hold" rating in a research note on Monday, November 17th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. The company currently has an average rating of 'Hold' and a consensus target price of $17.56.
You May Also Like